Fed. Circ. Partially Revives AstraZeneca Asthma Drug IP Row

Law360, Los Angeles (October 30, 2013, 4:08 PM EDT) -- The Federal Circuit on Wednesday reversed a lower court’s non-infringement ruling on one patent in an intellectual property dispute over AstraZeneca PLC’s Pulmicort Respules pediatric asthma medication but upheld the court’s finding of obviousness on a second patent, among other issues.

The decision comes after AstraZeneca asked the appeals court in August to block four generic-drug makers from launching no-name versions of the pediatric asthma medication, which uses a nebulizer and is directed for use with children, saying the lower court relied too heavily on expert...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.